Paresh Shah, MD
Clinical Cardiac Electrophysiology · Baltimore, MDNPI 1740274414
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Abbott at 48.1% of the total. Reporting peaked in 2021 at $27,720 and has fallen 67.0% since, to $9,143 in 2025. Among clinical cardiac electrophysiology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 498 payments — averaging $194.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$47K
- Sanofi-aventis U.S. LLC$20K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$7K
- E.r. Squibb & Sons, L.L.C.$6K
- Boston Scientific$6K
- Medtronic$4K
- plus $8K from 32 others
Across 4 payments — averaging $1512.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$6K
What the payments were for
- Consulting fees$47,54649%
- Speaking & faculty fees$30,46432%
- Travel & lodging$4,3254%
- Food & beverage$14,31815%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 151 | $46,540 |
| Sanofi-aventis U.S. LLC | 24 | $19,618 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $6,716 |
| E.r. Squibb & Sons, L.L.C. | 25 | $6,201 |
| Boston Scientific | 37 | $5,870 |
| Medtronic(2 entities) | 63 | $3,876 |
| Pfizer | 30 | $3,304 |
| Johnson & Johnson | 29 | $462 |
| Novartis | 18 | $435 |
| Atricure, Inc. | 9 | $423 |
| Edwards Lifesciences | 3 | $416 |
| Boehringer Ingelheim | 11 | $339 |
| Merck | 17 | $278 |
| Biosense Webster, Inc. | 3 | $271 |
| Irhythm Technologies, Inc. | 8 | $242 |
| AstraZeneca | 8 | $234 |
| Inari Medical, Inc. | 2 | $189 |
| Intuitive Surgical | 2 | $186 |
| Cvrx, Inc. | 1 | $138 |
| Esperion Therapeutics, Inc. | 1 | $120 |
| Bardy Diagnostics, Inc. | 4 | $104 |
| Stryker | 1 | $103 |
| Preventice Services, LLC | 1 | $89 |
| Bayer | 4 | $74 |
| Lundbeck LLC | 4 | $55 |
| Biotronik Inc. | 3 | $52 |
| Philips North America LLC | 3 | $52 |
| Kestra Medical Technology Services, Inc. | 1 | $49 |
| Chiesi USA, Inc. | 3 | $47 |
| Itamar Medical Inc | 2 | $26 |
| Abiomed | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Tactile Systems Technology Inc | 1 | $18 |
| GE HealthCare | 1 | $17 |
| Gilead | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MULTAQ$15,247
- Accent Pacemaker$13,200
- ELIQUIS$8,735
- LifeVest$6,000
- GALLANT$4,916
- ACCENT$4,800
- ALLURE$4,500
- DISEASE STATE$4,134
- Farapulse$3,349
- Fortify Assura, Ellipse ICD$2,660
- QUADRA ASSURA$2,400
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,400
- Ensite Cardiac Mapping System$1,995
- Endurity Pacemaker$1,710
- Watchman$1,613
- Anthem CRT Pacemaker$1,520
- Allure CRT Pacemaker$1,425
- Quadra Assura CRT Defibrillator$1,235
- Arctic Front$1,143
- Unify Assura CRT Defibrillator$855
How this compares
$96,658 in reported general payments places this provider in the 95th percentile of 63 clinical cardiac electrophysiology providers in Maryland.
See all clinical cardiac electrophysiology providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 552 | $669,378 |
| XareltoRivaroxaban | 157 | $184,726 |
| EntrestoSacubitril/Valsartan | 118 | $172,881 |
| JardianceEmpagliflozin | 171 | $166,089 |
| FarxigaDapagliflozin Propanediol | 82 | $70,012 |
| Dofetilide | 28 | $16,506 |
| Metoprolol Succinate | 584 | $10,291 |
| Flecainide Acetate | 208 | $8,151 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 28 | $8,067 |
| Amiodarone Hcl | 270 | $6,631 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 150 | $5,749 |
| Digoxin | 106 | $2,962 |
| Atorvastatin Calcium | 201 | $2,639 |
| Mexiletine Hcl | 16 | $2,249 |
| Amlodipine Besylate | 166 | $1,846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $3,304 | $669,378552 claims |
| Johnson & JohnsonXarelto | $462 | $184,726157 claims |
| NovartisEntresto | $435 | $172,881118 claims |
| Boehringer IngelheimJardiance | $339 | $166,089171 claims |
| AstraZenecaFarxiga | $234 | $70,01282 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 63 clinical cardiac electrophysiology providers in Maryland.
Other clinical cardiac electrophysiology in Baltimore
- Charles LoveBaltimore$238K
- Hugh CalkinsBaltimore$202K
- Jonathan ChrispinBaltimore$77K
- Stephen ShorofskyBaltimore$63K
- Richard JonesBaltimore$49K
- Benjamin RosenBaltimore$41K
- Zeshan AhmadBaltimore$37K
- Ronald BergerBaltimore$26K
- Klitos KonstantinidisBaltimore$24K
- Sunjeet SidhuBaltimore$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.